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Results: Compared to patients transferred without thrombolytic therapy (NOTHRM),
patients transferred on thrombolytic therapy (THRM) had a lower rate of mortality post
PCI (3.2% vs. 5.8%; p <0.0001), less post-PCI renal failure (1.4% vs. 2.2%; p<0.0001)
and were less like to have emergency surgery post PCI (0.4% vs. 0.7%). Based on a val-
idated mortality risk model, the observed mortality of the THRM patients was identical to
the expected mortality from the model (ratio O/E=1.0), whereas the NOTHRM patients
had a much worse than expected observed mortality (ratio O/E=1.4). Total occlusion of
the infarct-related artery was found less frequently on angiography in THRM compared to
NOTHRM (24.7% vs. 49.2%; p<0.0001).
Conclusion: In the setting of STEMI, transferred patients who received thrombolytic
therapy had better outcomes following PCI than those who did not. Transferred patients
who did not receive thrombolytics had higher PCI mortality, perhaps due to an increased
rate of occluded infarct-related artery prior to PCI. Further studies are needed to evaluate
the benefit of combined thrombolytic therapy and transfer PCI in the setting of STEMI.
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883-2 The Association of Race With Angiographic and Clinical 
Outcomes Following Fibrinolytic Administration
Pedro Martinezclark, Dimitri Karmpaliotis, Sabrina A. Murphy, Stephen D. Wiviott, Brian 
Bigelow, Ioanna Kosmidou, Allen Chang, Christopher P. Cannon, Robert P. Giugliano, C. 
Michael Gibson, Beth Israel Deaconess Medical Center, Boston, MA, TIMI Data 
Coordinating Center, Boston, MA
Background: The association of race with angiographic and clinical outcomes following
fibrinolytic administration is unclear. Objectives and Methods: To assess whether there
are racial differences in response to fibrinolytic administration in the treatment of acute
myocardial infarction. A total of 17,663 patients (16,366 Caucasians and 1,297 non-Cau-
casians) from the TIMI 4, 10A, 10B, and 14 and InTIME-2 trials were analyzed. TIMI flow
grade (TFG), corrected TIMI frame count (CTFC), TIMI myocardial perfusion grade
(TMPG), and electrocardiographic (ECG) data were available in 2,596 patients. Results:
Baseline comorbidities were increased among non-Caucasians including the incidence
of hypertension (p<0.001), diabetes (p<0.001), active cigarette smoking (p=0.006) and a
longer time to treatment (p<0.001). Angiographic outcomes did not differ by race when
stratified by use of low dose fibrinolysis combined with full dose platelet glycoprotein IIb/
IIIa receptor inhibition. Mortality was significantly lower among African-American patients
vs others (2.64% vs. 6.45%, p=0.012), even when adjusting for age, gender, systolic
blood pressure, pulse, history of hypertension, diabetes, or CHF, prior MI, Killip class on
admission, smoking, anterior MI location, and time to treatment (O.R. 0.34, 95% CI 0.12-
0.92, p=0.034). Recurrent MI trended lower in African-American patients (3.0% vs. 5.0%,
p=0.15). The composite of death or recurrent MI was significantly lower in African-Ameri-
can patients (5.3% vs 10.6%, p=0.005) as was CHF (3.8% vs 10.25%, p=0.001). How-
ever, when region of the patients’ enrollment (North American, Latin American, Eastern
Europe, Western Europe) was added to the model, the odds ratio for neither death nor
the composite of death/MI remained significant. There was no difference in the incidence
of ICH or major bleeding complications. Conclusion: After adjustment for baseline char-
acteristics and geographic region of enrollment, race was not independently associated
with clinical outcomes.
11:00 a.m.
883-3 Effects of Fish Oil Supplements on Human Myocardial 
Omega-3 Fatty Acid Levels and Correlations With 
Erythrocytes
Scott A. Sands, Hakim Ali, Phillip Mann, Anthony Magalski, Tracy L. Stevens, William S. 
Harris, Mid America Heart Institute, Kansas City, MO, University of Missouri-Kansas City, 
Kansas City, MO
Background: Omega-3 fatty acids (FA) have beneficial effects on the cardiovascular sys-
tem and are now recommended by the American Heart Association (AHA). Their primary
effect appears to be a reduction in risk for sudden cardiac death. Cell culture and animal
experiments suggest that once incorporated into the myocardium, omega-3 FA [espe-
cially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] increase the resis-
tance of the heart to ventricular fibrillation, apparently by altering the dynamics of sodium
and calcium channel function. However, whether the omega-3 FA tissue levels achieved
in these in vitro experiments was physiologically meaningful or not is unknown. The pur-
poses of this study were to determine the effects of supplementation with AHA-recom-
mended amounts of omega-3 FA on human myocardial FA composition, and to compare
the response of the heart to that of a more readily available tissue, the red blood cell
(RBC).
Methods: Twenty-one, medically-stable heart transplant recipients at least 3 months post
transplant were recruited. Heart biopsies and blood samples were obtained before and
after 6 months supplementation with 1 g/day of EPA+DHA (600 mg EPA and 400 mg
DHA; Ocean Nutrition Canada, Nova Scotia, Canada). The extent of omega-3 FA incor-
poration into these tissues was examined using gas chromatography.
Results: Supplementation raised the EPA+DHA content of the heart by 73% and of the
RBC by 93% (p=0.001 for both). The increases differed for these two FA, however. In the
heart, EPA increased by 216% (from 0.2% to 0.6% of total FA) and in the RBC by 257%
(from 0.4% to 1.5%). For DHA, the increases were 54% in the heart (from 1.5% to 2.3%)
and 78% in the RBC (from 4.2% to 7.8%).
Conclusion: These findings indicate that AHA-recommended intakes of omega-3 FA sig-
nificantly increase human myocardial EPA+DHA content, and that these changes may be
tracked by measurement of RBC EPA+DHA. The myocardial omega-3 FA levels
observed here may be used as physiologically-relevant benchmarks for future in vivo and
in vitro experiments to explore the cellular mechanisms responsible for the cardioprotec-
tive effects of omega-3 FA.
11:15 a.m.
883-4 Myocardial Ischemia-Reperfusion Injury Is Dependent 
on Lectin Complement Activation
Mary C. Walsh, Todd Bourcier, Kazue Takahashi, Lei Shi, Alan Ezekowitz, Gregory L. 
Stahl, Brigham and Women's Hospital, Boston, MA, Massachusetts General Hospital, 
Boston, MA
Background: Complement C5 activation mediates myocardial injury following myocar-
dial ischemia-reperfusion (MI/R). Complement activation is thought to result from natural
antibodies binding to neo-epitopes on injured cells, resulting in classical pathway activa-
tion and PMN infiltration. Therefore, we evaluated the contribution of the lectin and classi-
cal pathway in MI/R injury using MBL-null (MBL-A/CKO), C1q-deficient (C1qKO), C2- and
factor B-deficient (C2/Bf) or wild-type (WT) mice.
Methods: The LAD of each experimental animal was reversibly ligated for 30 min, fol-
lowed by 3 h of reperfusion. After 3 h the LAD was re-ligated to establish healthy tissue
and area at risk myocardium. Hearts were then stained for infarction and C3 or C1q dep-
osition. Myocardial infarction (MI) is expressed as a percentage of the area at risk (inf-
arct/area at risk x 100).
Results: MI/R induced significantly larger MI in WT, compared to C2/Bf mice (33±2 vs.
12±2%, respectively; p<0.05). Addition of human C2 to C2/Bf significantly increased MI
to 43±9%, comparable to WT mice and demonstrating that MI/R injury is mediated via
classical and/or lectin pathway activation. WT or C1qKO mice undergoing MI/R demon-
strated myocardial C3 deposition, thus demonstrating complement activation. WT mice
following MI/R demonstrated C1q deposition in the myocardium, whereas C1qKO mice
did not. C1qKO mice demonstrated a MI of 47±7%, and anti-C5 mAb treatment signifi-
cantly (p<0.05) reduced the infarction to 12±4%. Additionally, MBL null mice demonstrate
significantly decreased MI (4+2%; p<0.05) in comparison to WT mice following experi-
mental MI/R. However, addition of recombinant MBL to MBL null mice significantly
increased MI to 25±8%.
Conclusions: Collectively, these data demonstrate that complement activation contrib-
utes to MI/R injury. The complement system is not activated during MI/R by a C1q depen-
dent mechanism, yet C1q is deposited. Importantly, MBL null mice demonstrate little to
no infarct following experimental MI/R, yet injury is re-established upon addition of MBL.
Ultimately, these findings demonstrate the therapeutic potential of lectin complement
pathway blockade in MI/R and ischemic heart disease.
11:30 a.m.
883-5 Cardioprotective Effects of Rosiglitazone Against 
Ischemia-Reperfusion Injury Are Associated With 
Modulation of Angiotensin Receptor Expression and 
Signaling
Behzad Molavi, Jawahar L. Mehta, University of Arkansas for Medical Sciences, Little 
Rock, AR, Central Arkansas Veterans Healthcare System, Little Rock, AR
Background
Myocardial ischemia-reperfusion injury is associated with the upregulation of renin-
angiotensin system, which accentuates ischemia-reperfusion injury. The PPAR-γ ligand
rosiglitazone has been shown to exert anti-inflammatory and cardioprotective effects dur-
ing ischemia-reperfusion. We hypothesized that the cardioprotection by rosiglitazone is
associated with alterations in angiotensin II (Ang II) receptor expression.
Methods
Male S-D rats were fed either a rosiglitazone-rich diet (3mg/kg/d) or regular rat chow
(control diet group) and subjected to ischemia-reperfusion (n=9 each group). A third
group of rats was fed regular chow and subjected to thoracotomy and left coronary isola-
tion (sham ischemia-reperfusion). At the end of the study, hearts were harvested for inf-
arct size determination as well as immunohistochemistry and Ang II AT1 and AT2
receptor mRNA determination by real-time reverse transcription polymerase chain reac-
tion (RT-PCR). The expression of mitogen-activated protein kinase (P42/44 MAPK) and
protein kinase B/Akt was assessed by Western blotting.
Results
The cardioprotective effects of rosiglitazone were confirmed by 58% reduction in infarct
size (P<0.05) and preservation of myocardial contractility (decline in ± dP/dt 75% less in
the rosiglitazone-rich diet group) during reperfusion (P<0.005). Importantly, Ang II AT2
receptor mRNA expression was markedly (≅100-fold) increased in the hearts from the
rats on rosiglitazone-rich diet as compared to those on the control-diet (P<0.005). The
Ang II AT1 receptor expression, which was increased in the control-diet group subjected,
was suppressed (≅8-fold) by rosiglitazone (P<0.005). P42/44 MAPK was increased in the
cotrol diet group, and this effect was ameliorated by rosiglitazone. Akt expression was
similar among the three groups, suggesting that insulin signaling was not involved in car-
dioprotection by rosiglitazone.
Conclusion
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Cardioprotection by rosiglitazone against ischemia-reperfusion involves upregulation of
AT2 and downregulation of AT1 receptors. P42/44 MAPK is also inhibited by rosiglita-
zone. Insulin signaling is not involved in cardioprotection by rosiglitazone.
11:45 a.m.
883-6 Carbon Monoxide Protects Against Cardiac Ischemia-
Reperfusion Injury In Vivo Through Mitogen-Activated 
Protein Kinanse Pathway and Akt-Endothelial Nitric 
Oxide Synthase Pathway
Hajime Fujimoto, Seiji Ayabe, Nobukazu Ishizaka, Minoru Ohno, Ryozo Nagai, University 
of Tokyo, Tokyo, Japan
Background: Heme oxygenase-1 (HO-1) is an endogenous anti-stress enzyme that
catabolizes heme to free iron, carbon monoxide (CO), and biliverdin. Recently, CO is
postulated to play a protective role against tissue injury induced by several stresses. In
this study, we investigated the role of CO in amelioration of cardiac ischemia-reperfusion
injury, and the mechanism involved in it. Methods and Results: Rats inhaled CO (250
ppm, 500 ppm, or 1000 ppm, balanced with air) or room air for 24 hr in a chamber. Then
the left anterior descending coronary artery was occluded for 30 min, followed by 120
min reperfusion, during which they continued inhaling CO or room air. CO had no effects
on body temperature or hemodynamic parameters before ischemia-reperfusion. Pre-
treatment with 1000 ppm of CO, but not 250 ppm nor 500 ppm, significantly reduced the
ratio of the infarct area to the risk area (I/R ratio; room air 35 ± 4 % vs. 1000 ppm CO 6 ±
2 %, P < 0.001), and suppressed the migration of macrophages and monocytes, and the
expression of tumor necrosis factor-a (TNF-a) in the risk areas (P < 0.05, those with 1000
ppm CO vs. without CO). Inhalation of 1000 ppm CO elevated HbCO up to 30% in blood.
Thus, tissue hypoxia–induced preconditioning is suspected to be responsible for this phe-
nomenon. However, the simple hypoxia (under 0.5 atom air for 24 hr) did not reduce I/R
ratio. CO activated MAPKs (p38, JNK, and ERK), Akt, and eNOS in the heart within 12
hours; although neither 250 ppm nor 500 ppm CO nor exposure to the simple hypoxia
activated them. Pre-treatment with SB203580, or wormannin completely blocked the acti-
vation of p38, or Akt and eNOS, respectively. They disturbed the cytoprotective effects of
CO additively (I/R ratio; 20 ± 3% (SB203580 + CO), 23 ± 2 % (wortmannin + CO), and 39
± 4 % (SB203580 + wortmannin + CO) vs. those with vehicle + CO; 9 ± 3 %, respectively,
P < 0.05). L-NAME (an inhibitor of NO production) also attenuated the tissue protection
by CO to almost to the same level as wortmannin (I/R ratio; 22 ± 5 % (L-NAME+CO)).
Conclusion: CO protects heart from ischemia-reperfusion injury. P38 pathway and Akt-
eNOS pathway are the key pathways in the cytoprotective effect of CO.
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884-2 Cardiac Dysfunction in Non-ST Elevation ACS Is Partly 
Reversible: Analysis of Serial Measurements of NT-Pro 
B-Type Natriutetic Peptide
Bertil Lindahl, Nina Johnston, Tomas Jernberg, Matts Stridsberg, Per Venge, Lars 
Wallentin, The FRISK-II Study Group, University Hospital, Uppsala, Sweden
The inactive form of B-type Natriuretic Peptide, NT-proBNP, is a marker of acute as well
of chronic cardiac dysfunction. NT-proBNP is markedly elevated in acute nonSTE-ACS
and elevated levels are associated with an increased short- and long-term mortality.
However, little is known about the temporal changes of NT-proBNP and their causes after
an episode of nonSTE-ACS.
Methods: NT-proBNP was measured at inclusion in the study, after 6 weeks, 3 and 6
months together with Troponin T and C-Reactive Protein at inclusion in 642 patients
included in the FRISC-II invasive trial. The association between changes of NT-proBNP
over time and a number of clinical and laboratory parameters was evaluated by multiple
linear regression analysis.
Results: The NT-proBNP level decreased in median 172 ng/L (25th-75th perc.; 2-671)
from inclusion to 6 months. There was no significant statistically change in patients with-
out any myocardial damage (tnT <0.01 µg/L). In patients with myocardial damage (tnT
>0.01 µg/L) higher levels of tnT and CRP were associated with a larger decrease in NT-
proBNP, whereas higher weight, a history of diabetes, smoking and chronic heart failure,
respectively, were associated with increasing NT-proBNP levels.
Conclusion: Cardiac dysfunction, as measured by NT-proBNP, is to a large extent
reversible in nonSTE-ACS patients. Reversible dysfunction is associated with tnT and
CRP elevation. Irreversible dysfunction is associated with diabetes, chronic heart failure,
smoking and weight. 
11:00 a.m.
884-3 Clinical Implications of Discordant Creatine Kinase-MB 
and Troponin Results in Patients With Acute Coronary 
Syndromes
L. Kristin Newby, Eric D. Peterson, Anita Chen, Robert A. Harrington, Charles V. Pollack, 
Jr., James W. Hoekstra, Robert H. Christenson, Robert L. Jesse, W. Brian Gibler, E. 
Magnus Ohman, Matthew T. Roe, Duke Clinical Research Institute, Durham, NC, 
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Creatine kinase-MB (CKMB) and cardiac troponins (Tn) are often mea-
sured concurrently in patients with non–ST-segment elevation acute coronary syndromes
(NSTE ACS). The significance of discordant CK-MB and Tn results remains controversial
and their effect on ACS care delivery is unknown.
Methods: Among 29,357 NSTE ACS patients in the CRUSADE Initiative who had both
CKMB and Tn measured during the first 36 hours, we examined relationships of 4 combi-
nations of marker results (CKMB-/Tn-, CKMB+/Tn-, CKMB-/Tn+, CKMB+/Tn+) with clini-
cal outcomes and use of ACC/AHA guidelines-recommended acute management
strategies. (Markers considered + if above upper limit of normal.)
Results: 28% had discordant CKMB and Tn results (10% CKMB+/Tn-; 18% CKMB-/
Tn+). Results are shown in the Table. Patterns were similar after excluding patients with
renal insufficiency.
Conclusions: Mortality in Tn+ patients is increased regardless of CKMB status, but
CKMB elevation in the absence of elevated Tn does not predict increased mortality. Par-
adoxically, use of GPIIb-IIIa and early invasive strategies among Tn+ patients appears
biased by CKMB results despite this risk pattern and that the bulk of evidence for use is
based on Tn+ status. Recognition of these risk differences may contribute to more appro-
priate early use of antiplatelet therapy and early invasive management strategies for all
Tn+ patients. 
11:15 a.m.
884-4 Higher Levels of Thrombus Precursor Protein Are 
Associated With Increased Death and Ischemic 
Complications in Patients With Acute Coronary 
Syndromes
Jessica L. Mega, Marc S. Sabatine, David A. Morrow, James A. de Lemos, Sabina A. 
Murphy, Carolyn H. McCabe, Christopher P. Cannon, Eugene Braunwald, TIMI Study 
Group, Brigham and Women's Hospital, Boston, MA
Background: Thrombus Precursor Protein (TpP), which measures soluble fibrin, is a
marker of active thrombosis. We evaluated the relationship between TpP and clinical out-
comes in patients with acute coronary syndromes (ACS).
Methods: Baseline TpP levels were measured in 2349 patients with ACS enrolled in
OPUS-TIMI 16. Death, nonfatal MI, recurrent ischemia requiring urgent revascularization
(Urg Revasc), and severe ischemia leading to rehospitalization (Sev Isch) were evaluated
Use of guideline-recommended acute treatment strategies (medications given within 24 
hours) and clinical outcome by marker category
CKMB-/Tn-
(n=3,502)
CKMB+/Tn-
(n=2,988)
CKMB-/Tn+
(n=5,349)
CKMB+/Tn+
(n=17,518)
Aspirin (%) 89 91 91 92
B-blocker (%) 70 70 76 79
Heparin (%) 71 72 76 87
GP IIb-IIIa (%) 18 24 23 38
Cath <48 hrs (%) 39 36 35 45
PCI (%) 31 31 29 36
In-hospital death (%) 2.71 2.95 4.45 5.87
